Reuters logo
BRIEF-Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1
2017年5月1日 / 上午10点41分 / 7 个月前

BRIEF-Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1

May 1 (Reuters) - Neurotrope Inc :

* Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1 for moderate to severe Alzheimer’S disease

* Results indicate 20 μg dose,administered every 2 weeks,met pre-specified primary endpoint in Completer population, not in mITT population

* Data indicate that Bryostatin-1 improves cognition and ability to perform activities of daily living

* Plans to meet with FDA to address clinical and regulatory path forward for Bryostatin-1 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below